ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • hormones and lupus nephritis
  • hormones and nephritis
  • hormones and neuropsychiatric disorders
  • hormones and ovarian
  • hormones and population studies
  • hormones and prolactin
  • hormones and rheumatoid arthritis (RA)
  • hormones and sex hormones
  • hormones and systemic lupus erythematosus
  • hormones and systemic lupus erythematosus (SLE)
  • hormones and systemic sclerosis
  • Hospital admissions
  • hospitalization
  • hospitalization and mortality
  • hospitalization and rituximab
  • Hospitalization Rates
  • hotair
  • Hounsfield Units
  • HPK1
  • hpv
  • HR-pQCT
  • HR-pQCT and bone density
  • HR-pQCT and DXA
  • HR-pQCT and fractures
  • HR-pQCT and imaging techniques
  • HR-pQCT and rheumatoid arthritis (RA)
  • HR-pQCT and strength
  • HR-pQCT and treatment
  • Hsp90
  • Hsp90 and systemic sclerosis
  • Human AME
  • human and mouse model
  • human leukocyte antigens (HLA)
  • human leukocyte antigens (HLA) and Genetic Biomarkers
  • human leukocyte antigens (HLA) and interstitial lung disease
  • human leukocyte antigens (HLA) and juvenile idiopathic arthritis (JIA)
  • human leukocyte antigens (HLA) and major histocompatibility complex (MHC)
  • human leukocyte antigens (HLA) and methylation
  • human leukocyte antigens (HLA) and monocytes
  • human leukocyte antigens (HLA) and natural killer (NK) cells
  • human leukocyte antigens (HLA) and neonatal lupus
  • human leukocyte antigens (HLA) and osteoarthritis
  • human leukocyte antigens (HLA) and polymorphism
  • Human leukocyte antigens (HLA) and polymyositis/dermatomyositis (PM/DM)
  • human leukocyte antigens (HLA) and proteinuria
  • human leukocyte antigens (HLA) and pulmonary complications
  • human leukocyte antigens (HLA) and race/ethnicity
  • human leukocyte antigens (HLA) and rheumatoid arthritis (RA)
  • human leukocyte antigens (HLA) and scleroderma
  • human leukocyte antigens (HLA) and spondylarthritis
  • human leukocyte antigens (HLA) and spondylarthropathy
  • human leukocyte antigens (HLA) and statins
  • human leukocyte antigens (HLA) and statistics
  • Human leukocyte antigens (HLA) and systemic lupus erythematosus (SLE)
  • human leukocyte antigens (HLA) and systemic sclerosis
  • human leukocyte antigens (HLA) and treatment
  • human leukocyte antigens (HLA) and vasculitis
  • Human papillomavirus (HPV)
  • human papillomavirus (HPV) and pediatric rheumatology
  • human papillomavirus (HPV) and rheumatoid arthritis (RA)
  • Human papillomavirus (HPV) and systemic lupus erythematosus (SLE)
  • human papillomavirus (HPV) and vaccines
  • human resources
  • human resources and educational research
  • human resources and osteoarthritis
  • Hyaluronan
  • hyaluronate
  • hyaluronate and osteoarthritis
  • hyaluronate and viscosupplementation
  • hyaluronic acid
  • hydralazine
  • hydralazine associated vasculitis
  • Hydroxyapatite Deposition Disease/Calcific Periarthritis
  • Hydroxychloroquine
  • hydroxychloroquine and autoantibodies
  • hydroxychloroquine and complement
  • hydroxychloroquine and Disease Activity
  • hydroxychloroquine and juvenile dermatomyositis
  • hydroxychloroquine and lupus nephritis
  • hydroxychloroquine and neonatal disorders
  • hydroxychloroquine and outcome measures
  • hydroxychloroquine and outcomes
  • hydroxychloroquine and polymorphism
  • hydroxychloroquine and prednisolone
  • hydroxychloroquine and pregnancy
  • hydroxychloroquine and prevention
  • hydroxychloroquine and quality
  • hydroxychloroquine and quality improvement
  • Hydroxychloroquine and quality measures
  • hydroxychloroquine and quality of life
  • hydroxychloroquine and retinopathy
  • Hydroxychloroquine and rheumatic disease
  • hydroxychloroquine and rheumatoid arthritis (RA)
  • hydroxychloroquine and safety
  • hydroxychloroquine and systemic lupus erythematosus (SLE)
  • hydroxychloroquine and thrombosis
  • hydroxychloroquine and tumor necrosis factor (TNF)
  • hydroxychloroquine and vasculitis
  • hypercoagulable
  • hyperlipidemia
  • hypermobility
  • hypermobility and mast cells
  • hypermobility and pain
  • Hypermobility and physical function
  • hypermobility and posture
  • Hypermobility and rheumatic disease
  • Hypermobility and systemic lupus erythematosus (SLE)
  • hypertension
  • hypertension and cardiovascular disease
  • hypertension and hyperuricemia
  • hypertension and lupus nephritis
  • hypertension and morbidity and mortality
  • hypertension and nonsteroidal antiinflammatory drugs (NSAIDs)
  • Hypertension and osteoarthritis
  • hypertension and pediatric rheumatology
  • hypertension and prevention
  • hypertension and renal disease
  • hypertension and rheumatoid arthritis (RA)
  • hypertension and rheumatologic disease
  • hypertension and steroids
  • Hypertension and systemic lupus erythematosus (SLE)
  • hypertension and treatment
  • hypertension and uric acid
  • hypertrophy
  • hyperuricemia
  • Hyperuricemia (HUC)
  • hyperuricemia and inflammation
  • hyperuricemia and mean arterial blood pressure
  • hyperuricemia and meta-analysis
  • hyperuricemia and metabolic syndrome
  • hyperuricemia and morbidity and mortality
  • hyperuricemia and osteoarthritis
  • hyperuricemia and osteoporosis
  • hyperuricemia and outcomes
  • hyperuricemia and pediatrics
  • Hyperuricemia and polymorphism
  • hyperuricemia and population studies
  • hyperuricemia and prescribing trends
  • Hyperuricemia and psoriatic arthritis
  • hyperuricemia and quality of care
  • Hyperuricemia and quality of life
  • hyperuricemia and renal disease
  • hyperuricemia and rheumatoid arthritis (RA)
  • hyperuricemia and risk assessment
  • hyperuricemia and safety
  • hyperuricemia and tophaceous gout
  • hyperuricemia and ultrasonography
  • hyperuricemia and uric acid
  • hyperuricemia and young adults
  • Hypophosphatasemia and Metabolic bone diseases
  • hypophosphatasia
  • hypoxia
  • ibandronate
  • ibandronate and large vessel vasculitis
  • ibandronate and osteoporosis
  • Ibuprofen
  • Ibuprofen and pain
  • IC50
  • ICD-10
  • ICD-10 and data collection
  • ICD-9
  • ICD-9 and systemic lupus erythematosus (SLE)
  • ICOS
  • Idiopathic Inflammatory Myopathies (IIM)
  • Idiopathic Inflammatory Myopathies (IIM) and capillaroscopy
  • Idiopathic Inflammatory Myopathies (IIM) and classification criteria
  • Idiopathic Inflammatory Myopathies (IIM) and creatinine kinase
  • Idiopathic Inflammatory Myopathies (IIM) and haq
  • Idiopathic Inflammatory Myopathies (IIM) and interstitial lung disease
  • Idiopathic Inflammatory Myopathies (IIM) and intravenous immunoglobulin (IVIG)
  • Idiopathic Inflammatory Myopathies (IIM) and juvenile dermatomyositis
  • Idiopathic Inflammatory Myopathies (IIM) and lipids
  • Idiopathic Inflammatory Myopathies (IIM) and muscle biopsy
  • Idiopathic Inflammatory Myopathies (IIM) and mycophenolate mofetil
  • Idiopathic Inflammatory Myopathies (IIM) and myositis
  • Idiopathic Inflammatory Myopathies (IIM) and prognostic factors
  • Idiopathic Inflammatory Myopathies (IIM) and quality of life
  • Idiopathic Inflammatory Myopathies (IIM) and rituximab
  • Idiopathic Inflammatory Myopathies (IIM) and Sexuality
  • Idiopathic Inflammatory Myopathies (IIM) and T cells
  • Idiopathic thrombocytopenic purpura - ITP
  • Idiopathis Inflammatory Myopathies (IIM)
  • Idiopathis Inflammatory Myopathies (IIM) and juvenile myositis
  • IF
  • IFN
  • IFNB
  • IFNk
  • iga
  • IgA sequencing
  • IgA vasculitis
  • IgG
  • IgG4
  • IgG4 Related Disease
  • IgG4 Related Disease and autoantibodies
  • IgG4 Related Disease and biomarkers
  • IgG4 Related Disease and clinical research
  • IgG4 Related Disease and clinical trials
  • IgG4 Related Disease and complement
  • IgG4 Related Disease and cyclophosphamide
  • IgG4 Related Disease and fibroblasts
  • First |
  • « Previous Page
  • 23
  • 24
  • 25
  • 26
  • 27
  • [28]
  • 29
  • 30
  • 31
  • 32
  • 33
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology